



1645 #7

Patent 267/033

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re the Application of: |) Group Art Unit: 1645 |
|--|----------------------------|
| RAMESHWAR, Pranela | Examiner: not yet RECEIVED |
| Serial No.: 10/039,272 | , RECEIVED |
| Filed: October 20, 2001 | MAY 1 6 2002 |
| For: HEMATOPOIETIC GROWTH FACTOR INDUCIBLE NEUROKININ-1 GENE | TECH CENTER 1600/2900 |

TRANSMITTAL FOR INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231 Sir:

I. DOCUMENTS ENCLOSED:

Applicant submits the following documents with this Transmittal Letter.

- (1) Information Disclosure Statement;
- (2) Form PTO-1449;
- (3) References AG to BN; and
- (4) Postcard.

LA-235769.1

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

| May 7, 2002 | | |
|-----------------|------|--|
| Date of Deposit | | |

Name of Person Mailing Paper

A Child III

Signature of Person Mailing Paper

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) or any fees required by this filing to Lyon & Lyon's Deposit Account No. 12-2475.

> Respectfully submitted, LYON & LYON LLP

22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP

633 W. Fifth Street, Suite 4700

Los Angeles, CA 90071

Phone: (213) 489-1600 Fax: (213) 955-0440

THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re the Application of: |) Group Art Unit: 1645 |
|--|---------------------------------|
| RAMESHWAR, Pranela | Examiner: not yet assigned IVED |
| Serial No.: 10/039,272 |) 16 2002 |
| Filed: October 20, 2001 | TECH CENTER 1600 2900 |
| For: HEMATOPOIETIC GROWTH FACTOR INDUCIBLE NEUROKININ-1 GENE | TECH CENTER. |

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

LA-235569.1

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

Rachel Marquez Name of Person Mailing Haper May 7, 2002 Signature of Person Mailing Paper

Date of Deposit

Information Disclosure Statement Filing Provision:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR §1.17(p) or any fees required by this filing to Lyon & Lyon's Deposit Account No. 12-2475.

Respectfully submitted, LYON & LYON LLP

Dated:

5/6/02

Bv

Sandra S. Fujiyama

Reg. No. 46,713

PATENT TRADEMARK OFFICE

LYON & LYON LLP

633 W. Fifth Street, Suite 4700

Los Angeles, CA 90071

Phone: (213) 489-1600 Fax: (213) 955-0440

ATTY. DOCKET NO. **SERIAL NO.** FORM PTO-1449 10/039,272 266/033 LIST OF PATENTS AND OTHER ITEMS FOR APPLICANTISS 2002 APPLICANT: MAMESHWAR, Pranela INFORMATION DISCLOSURE STATEMENT WAN FILING DATE: **GROUP:** October 20, 2001 (Use several sheets if necessary) **U.S. PATENT DOCUMENTS** FILING TECH CENTER 1600/2900 **EXAMINER** DATE NAME DATE DOCUMENT NUMBER INITIAL AA AB AC FOREIGN PATENT DOCUMENTS TRANSLATION SUB **EXAMINER** NO YES **CLASS CLASS** COUNTRY DATE DOCUMENT NUMBER INITIAL AD AE AF OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Abrahams et al., "Cyclic AMP regulates the expression of neurokinin, receptors by neonatal rat spinal neurons in culture," J. Neurochem., Vol. 73, No. 1, (1999) pp. 50-58 AG Adamus et al., "Effect of the neuropeptide substance P on the rat bone marrow-derived osteogenic cells in vitro, J. Cell. Biochem., Vol. 81, (2001) pp. 499-506 AH Bairoch et al., "The PROSITE database, its status in 1997," Nucleic Acid Res., Vol. 25, No. 1, (1997) pp. 217-221 ΑI Biggs et al., "A human Id-like helix-loop-helix protein expression during early development," Proc. Nat'l Acad. Sci. USA, Vol. 89, (1992) pp. 1512-1516 AJ Cooper et al., "Differential expression of Id genes in multipotent myeloid progenitor cells: Id-1 is induced by early- and late-acting cytokines while Id-2 is selectively induced by cytokines that drive terminal granulocytic differentiation," J. Cell. Biochem., Vol. 71, (1998) pp. 277-285 AK Corpet et al., "The ProDom database of protein domain families," Nucleic Acid Res., Vol. 26, No. 1, (1998) pp. 323-326 AL Gerard et al., "Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones," Biochemistry, Vol. 30, (1991) pp. 10640-10646 AM Hegde et al., "c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors," Blood, Vol. 94, No. 5, (9/1/1999) pp. 1578-1589 AN Ho et al., "Human monocytes and macrophages express substance P and neurokinin-1 receptor," J Immunol., Vol. 159, (1997) pp. 5654-5660 AO International Polycystic Kidney Disease Consortium, The, "Polycystic kidney disease: The complete structure of

| LA | -22 | 92 | 72. | 1 |
|----|-----|----|-----|---|
|----|-----|----|-----|---|

EXAMINER:

AP

AQ

AR

DATE CONSIDERED:

Ishiguro et al., "Id2 expression increases with differentiation of human myeloid cells," Blood, Vol. 87, No. 12,

Krause et al., "Structure, functions, and mechanisms of substance P receptor action," J. Invest. Dermatol., Vol. 98,

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

the PKD1 gene and its protein," Cell, Vol. 81, (1995) pp. 289-298

(1996) pp. 5225-5231

No. 6, (6/1992) pp. 2S-7S

FORM FTO-1449

LIST OF PATENTS AND OTHER ITEMS FOR APPLEANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO. 10/039,272

266/033 PAPPLICANT:

MAMESHWAR, Pranela

ALING DATE: October 20, 2001 **GROUP:**

PATENTS Maggi, "Tachykinins in the autonomic nervous system," Pharmacol. Res., Vol. 33, No. 3, (1996) pp. 9629020 AS Marriott et al., "IL-4 and IFN-y up-regulate substance P receptor expression in murine-peritoneal macrophages," J. JECH CENTER 1600/2900 Immunol., Vol. 165, No. 1, (2000) pp. 182-191 AT Massari et al., "Helix-Loop-Helix proteins: Regulators of transcription in eucaryotic organisms," Mol. Cell. Biol., Vol. 20, No. 2, (1/2000) pp. 429-440 AU Miura et al., "Pyk2 and Syk participate in functional activation of granulocytic HL-60 cells in a different manner," Blood, Vol. 96, No. 5,(9/1//2000) pp. 1733-1739 AV Muller-Sieburg et al., "The stromal cells' guide to the stem cell universe," Stem Cells, Vol. 13, (1995) pp. 477-486 AW Norton et al., "Id helix-loop-helix proteins in cell growth and differentiation," Trends Cell Biol., Vol. 8, (2/1998) AXpp. 58-65 Quinn et al., "Molecular models to analyse preprotachykinin-A expression and function," Neuropeptides, Vol. 34, No. 5, (2000) pp. 292-302 AY Rameshwar, "Substance P: A regulatory neuropeptide for hematopoiesis and immune functions," Clin. Immunol. Immunopath., Vol. 85, No. 2, (2000) pp. 129-133 ΑZ Rameshwar et al., "Hematopoietic regulation mediated by interactions among the neurokinins and cytokines," Leuk. Lymphoma, Vol. 28, (1997) pp. 1-10 BA Rameshwar et al., "Receptor induction regulates the synergistic effects of substance P with IL-1 and PDGF on the proliferation of bone marrow fibroblasts," J. Immunol., Vol. 158, (1997) pp. 3417-3424. BB Rameshwar et al., "Mimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P-immunoreactivity in patients with bone marrow fibrosis," Blood, Vol. 97, No. 10, (5/15/2001) pp. 3025-303 1. BC Rameshwar et al., "NF-κB as a central mediator in the induction of TGF-β in monocytes from patients with idiopathic myelofibrosis: An inflammatory response beyond the realm of homeostasis," J. Immunol., Vol. 165, (2000) pp. 2271-2277 BDRandall, "Characterization of a population of cells in the bone marrow that phenotypically mimics hematopoietic stem cells: resting stem cells or mystery population?" Stem Cells, Vol. 16, (1998) pp. 38-48 BE Roodman, "Cell biology of the osteoclast," Exp. Hematol., Vol. 27, (1999) pp. 1229-1241 BF Rost et al., "Combining evolutionary information and neural networks to predict protein secondary structure," Proteins, Vol. 19, (1994) pp. 55-72 BG Rost et al., "Prediction of protein structure at better than 70% accuracy," J. Mol. Biol., Vol. 232, (1993) pp. BH 584-599 Rupniak, "Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK1) antagonists," Tachykinins 2000, (2000) p. 2a \mathbf{BI} Singh et al., "Increased expression of preprotachykinin-1 and neurokinin receptors in human breast cancer cells. Implications for bone marrow metastasis," Proc. Nat'l Acad. Sci. USA, Vol. 97, No. 1, (1/4/2000) pp. 388-393 BJSonnhammer, E.L., G. Heijne, and A. Krogh. 1998. A hidden Markov model for predicting transmembrane helices in protein sequences. pp.175-182. In Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen (ed.), Proceedings of 6th International Conference on Intelligent Systems for Molecular Biology. Menlo Park, CA. BK Tabarowski et al., "Noradrenergic and peptidergic innervation of the mouse femur bone marrow," Acta. Histochem., Vol. 98, (1996) pp. 453-457 BL Weterman et al., "nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts," Int. J. Cancer, Vol. 60, (1995) pp. 73-81 BM Yao et al., "Neurokinin-1 expression and colocalization with glutamate and GABA in the hypothalamus of the cat," Mol. Brain Res., Vol. 71, (1999) pp. 149-158 BN

| LA | -22 | 92 | 7 | 2. | 1 |
|----|-----|----|---|----|---|
| | | | | | |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant